Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

6.5K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.5K
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems01:22

Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

330
Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug absorption...
330
Biopharmaceutics and Pharmacokinetics: Overview01:28

Biopharmaceutics and Pharmacokinetics: Overview

5.1K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
5.1K
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

491
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
491
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

2.1K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
2.1K
Drug Discovery: Overview01:26

Drug Discovery: Overview

13.4K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
13.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Review: application and opportunities for machine learning and artificial intelligence in preclinical immunogenicity risk assessment.

Frontiers in immunology·2026
Same author

The National PA Research Agenda: Research priorities identified by American Academy of Physician Associates leaders.

JAAPA : official journal of the American Academy of Physician Assistants·2026
Same author

Proceedings of the 2024 FDA-CRCG Workshop: Scientific and Regulatory Considerations for Assessment of Immunogenicity Risk for Generic Peptide and Oligonucleotide Drug Products.

The AAPS journal·2026
Same author

Proceedings of the 15<sup>th</sup> European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals.

mAbs·2025
Same author

Perspectives on the use of machine learning for ADME prediction at AstraZeneca.

Xenobiotica; the fate of foreign compounds in biological systems·2024
Same author

Computational approaches identify a transcriptomic fingerprint of drug-induced structural cardiotoxicity.

Cell biology and toxicology·2024

Related Experiment Video

Updated: Apr 10, 2026

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.7K

Early implementation of QbD in biopharmaceutical development: a practical example.

Jesús Zurdo1, Andreas Arnell2, Olga Obrezanova2

  • 1Research and Technology, Pharma & Biotech, Lonza Biologics PLC, Granta Park, Great Abington, Cambridge CB21 6GS, UK.

Biomed Research International
|June 16, 2015
PubMed
Summary

Integrating drug manufacturing and discovery using Quality by Design (QbD) methodologies can enhance R&D efficiency. Early risk assessment and developability strategies reduce risks, improve product quality, and accelerate patient access to new therapies.

More Related Videos

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

140
Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation
09:28

Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation

Published on: May 18, 2020

9.4K

Related Experiment Videos

Last Updated: Apr 10, 2026

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.7K
A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

140
Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation
09:28

Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation

Published on: May 18, 2020

9.4K

Area of Science:

  • Drug development
  • Biopharmaceutical manufacturing
  • Quality by Design (QbD)

Background:

  • Traditionally, low R&D efficiency in drug development is attributed to the discovery phase.
  • Manufacturing's critical role in product success is often underestimated.
  • A holistic approach integrating discovery and manufacturing is needed.

Purpose of the Study:

  • To demonstrate how integrating manufacturing and discovery activities can enhance overall R&D efficiency.
  • To introduce early risk assessment and developability methodologies for cost-effective risk reduction.
  • To explore the impact of these strategies on product quality, efficacy, and patient safety.

Main Methods:

  • Applying a holistic interpretation of Quality by Design (QbD) methodologies.
  • Utilizing developability methodologies and computational tools for early risk assessment.
  • Defining specific risk areas and their impact on product quality, efficacy, and safety.

Main Results:

  • Integrating manufacturing and discovery through QbD can significantly increase R&D efficiency.
  • Early risk assessment using developability approaches effectively mitigates development risks.
  • Implementation of these strategies can reduce drug attrition and enhance biopharmaceutical supply chain robustness.

Conclusions:

  • A holistic, QbD-integrated approach to drug development, emphasizing manufacturing and early risk assessment, is crucial for efficiency.
  • Developability strategies are key to mitigating risks, ensuring product quality, and improving patient safety.
  • Adoption of these methodologies can accelerate the delivery of novel therapeutics to patients.